186 related articles for article (PubMed ID: 18316573)
1. Linking antibody Fc domain to endostatin significantly improves endostatin half-life and efficacy.
Lee TY; Tjin Tham Sjin RM; Movahedi S; Ahmed B; Pravda EA; Lo KM; Gillies SD; Folkman J; Javaherian K
Clin Cancer Res; 2008 Mar; 14(5):1487-93. PubMed ID: 18316573
[TBL] [Abstract][Full Text] [Related]
2. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model.
Kisker O; Becker CM; Prox D; Fannon M; D'Amato R; Flynn E; Fogler WE; Sim BK; Allred EN; Pirie-Shepherd SR; Folkman J
Cancer Res; 2001 Oct; 61(20):7669-74. PubMed ID: 11606410
[TBL] [Abstract][Full Text] [Related]
3. Adeno-associated virus-mediated antiangiogenic gene therapy with thrombospondin-1 type 1 repeats and endostatin.
Zhang X; Xu J; Lawler J; Terwilliger E; Parangi S
Clin Cancer Res; 2007 Jul; 13(13):3968-76. PubMed ID: 17606731
[TBL] [Abstract][Full Text] [Related]
4. A 27-amino-acid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity.
Tjin Tham Sjin RM; Satchi-Fainaro R; Birsner AE; Ramanujam VM; Folkman J; Javaherian K
Cancer Res; 2005 May; 65(9):3656-63. PubMed ID: 15867360
[TBL] [Abstract][Full Text] [Related]
5. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors.
Gillies SD; Lan Y; Lo KM; Super M; Wesolowski J
Cancer Res; 1999 May; 59(9):2159-66. PubMed ID: 10232603
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve.
Celik I; Sürücü O; Dietz C; Heymach JV; Force J; Höschele I; Becker CM; Folkman J; Kisker O
Cancer Res; 2005 Dec; 65(23):11044-50. PubMed ID: 16322254
[TBL] [Abstract][Full Text] [Related]
7. Prostate-restricted replicative adenovirus expressing human endostatin-angiostatin fusion gene exhibiting dramatic antitumor efficacy.
Li X; Liu YH; Lee SJ; Gardner TA; Jeng MH; Kao C
Clin Cancer Res; 2008 Jan; 14(1):291-9. PubMed ID: 18172281
[TBL] [Abstract][Full Text] [Related]
8. Endostatin-cytosine deaminase fusion protein suppresses tumor growth by targeting neovascular endothelial cells.
Ou-Yang F; Lan KL; Chen CT; Liu JC; Weng CL; Chou CK; Xie X; Hung JY; Wei Y; Hortobagyi GN; Hung MC
Cancer Res; 2006 Jan; 66(1):378-84. PubMed ID: 16397252
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of ovarian cancer by RGD-P125A-endostatin-Fc fusion proteins.
Jing Y; Lu H; Wu K; Subramanian IV; Ramakrishnan S
Int J Cancer; 2011 Aug; 129(3):751-61. PubMed ID: 21225621
[TBL] [Abstract][Full Text] [Related]
10. Atrial natriuretic peptide-Fc, ANP-Fc, fusion proteins: semisynthesis, in vitro activity and pharmacokinetics in rats.
Mezo AR; McDonnell KA; Low SC; Song J; Reidy TJ; Lu Q; Amari JV; Hoehn T; Peters RT; Dumont J; Bitonti AJ
Bioconjug Chem; 2012 Mar; 23(3):518-26. PubMed ID: 22263969
[TBL] [Abstract][Full Text] [Related]
11. [Gene transfection of endostatin synergizes with doxorubicin to suppress human hepatocellular carcinomas: experiment with mice].
Liu FJ; Tan G; Li J; Sun XY
Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(30):2147-51. PubMed ID: 19080480
[TBL] [Abstract][Full Text] [Related]
12. Blockade of Wnt signaling inhibits angiogenesis and tumor growth in hepatocellular carcinoma.
Hu J; Dong A; Fernandez-Ruiz V; Shan J; Kawa M; Martínez-Ansó E; Prieto J; Qian C
Cancer Res; 2009 Sep; 69(17):6951-9. PubMed ID: 19690140
[TBL] [Abstract][Full Text] [Related]
13. Targeted delivery of an antibody-mutant human endostatin fusion protein results in enhanced antitumor efficacy.
Shin SU; Cho HM; Merchan J; Zhang J; Kovacs K; Jing Y; Ramakrishnan S; Rosenblatt JD
Mol Cancer Ther; 2011 Apr; 10(4):603-14. PubMed ID: 21393427
[TBL] [Abstract][Full Text] [Related]
14. Construction and preclinical characterization of Fc-mGITRL for the immunotherapy of cancer.
Hu P; Arias RS; Sadun RE; Nien YC; Zhang N; Sabzevari H; Lutsiak ME; Khawli LA; Epstein AL
Clin Cancer Res; 2008 Jan; 14(2):579-88. PubMed ID: 18223234
[TBL] [Abstract][Full Text] [Related]
15. Biochemical characterization of rhEpo-Fc fusion protein expressed in CHO cells.
Schriebl K; Trummer E; Lattenmayer C; Weik R; Kunert R; Müller D; Katinger H; Vorauer-Uhl K
Protein Expr Purif; 2006 Oct; 49(2):265-75. PubMed ID: 16861003
[TBL] [Abstract][Full Text] [Related]
16. Endostatin therapy reveals a U-shaped curve for antitumor activity.
Tjin Tham Sjin RM; Naspinski J; Birsner AE; Li C; Chan R; Lo KM; Gillies S; Zurakowski D; Folkman J; Samulski J; Javaherian K
Cancer Gene Ther; 2006 Jun; 13(6):619-27. PubMed ID: 16456550
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activities of TEM8-Fc: an engineered antibody-like molecule targeting tumor endothelial marker 8.
Duan HF; Hu XW; Chen JL; Gao LH; Xi YY; Lu Y; Li JF; Zhao SR; Xu JJ; Chen HP; Chen W; Wu CT
J Natl Cancer Inst; 2007 Oct; 99(20):1551-5. PubMed ID: 17925540
[TBL] [Abstract][Full Text] [Related]
18. Generation of mutant leukaemia inhibitory factor (LIF)-IgG heavy chain fusion proteins as bivalent antagonists of LIF.
Jazayeri JA; De Weerd N; Raye W; Velkov T; Santos L; Taylor D; Carroll GJ
J Immunol Methods; 2007 May; 323(1):1-10. PubMed ID: 17408687
[TBL] [Abstract][Full Text] [Related]
19. A truncated soluble epidermal growth factor receptor-Fc fusion ligand trap displays anti-tumour activity in vivo.
Adams TE; Koziolek EJ; Hoyne PH; Bentley JD; Lu L; Lovrecz G; Ward CW; Lee FT; Scott AM; Nash AD; Rothacker J; Nice EC; Burgess AW; Johns TG
Growth Factors; 2009 Jun; 27(3):141-54. PubMed ID: 19333814
[TBL] [Abstract][Full Text] [Related]
20. Half-life extension of a single-chain diabody by fusion to domain B of staphylococcal protein A.
Unverdorben F; Färber-Schwarz A; Richter F; Hutt M; Kontermann RE
Protein Eng Des Sel; 2012 Feb; 25(2):81-8. PubMed ID: 22238430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
